Recipient of federal assistance · ANN ARBOR, MI

TSRL, INC.

TSRL, INC. received $2.4M in federal grants and other assistance in FY2026, on 8 actions, −23% vs FY2025. It has no federal contracts in the loaded years. Since FY2021: $15.4M. Its largest awarding agency was National Institutes of Health ($2.1M).

Assistance · FY2026
$2.4M
New awards
1
Actions
8
Since FY2021
$15.4M
UEI
TP74UMNGJDJ1
Location
ANN ARBOR, MI
Businesses
Open in the explorerFederal grants & assistance

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

Assistance by fiscal year

  1. 952.2KFY2021
  2. 2.7MFY2022
  3. 2.9MFY2023
  4. 3.3MFY2024
  5. 3.1MFY2025
  6. 2.4MFY2026

By type

  1. Grants$2.4M100%

Top programs · Awarding agencies

Obligations in FY2026.

Top programs

  1. 93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research$1.1M46%
  2. 93.855 · Allergy and Infectious Diseases Research$999.2K42%
  3. 93.318 · Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security$299.6K13%

Awarding agencies

  1. National Institutes of Health$2.1M87%
    Department of Health and Human Services
  2. Centers for Disease Control and Prevention$299.6K13%
    Department of Health and Human Services

Largest awards

  1. DEVELOPMENT OF METHIONYL-TRNA SYNTHETASE INHIBITORS FOR GRAM POSITIVE BACTERIAL INFECTIONS$6M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Oct 14, 2021 – Jul 30, 2026· R44AI134190
  2. MICRONEEDLE DELIVERY OF ZANAMIVIR FOR TREATMENT OF INFLUENZA$5.9M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Mar 25, 2021 – Jan 21, 2026· R44AI129122
  3. NOVEL, SELF-APPLIED MICROARRAY PATCH (MAP) OF ZANAMIVIR FOR TREATMENT OF THE FLU - ABSTRACT YEARLY INFLUENZA EPIDEMICS STRIKE MILLIONS OF…$2.3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jul 27, 2023 – Jul 2, 2026· R44AI179506
  4. MICRONEEDLE DELIVERY OF TROSPIUM CHLORIDE OPTIMIZED FOR IMPROVED TOLERANCE AND PATIENT OUTCOMES IN OVERACTIVE BLADDER DISEASE - ABSTRACT…$2.2M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Sep 15, 2025 – Jul 9, 2026· R44DK143799
  5. PHASE 1 CLINICAL TRIAL TO ASSESS THE PHARMACOKINETICS, SAFETY AND TOLERANCE OF A ZANAMIVIR TRANSDERMAL SYSTEM IN HEALTHY SUBJECTS…$1.3M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Cooperative agreement· Jul 10, 2024 – Sep 3, 2026· U44AI184201
  6. OPTIMIZED ZANAMIVIR MICROARRAY PATCH (MAP) FORMULATION FOR SINGLE APPLICATION TREATMENT OF THE FLU$299.6K
    93.318 · Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security· Centers for Disease Control and Prevention· Project grant· Aug 15, 2026 – Sep 23, 2026· R43IP001280

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2021–FY2026.